Ask AI
Diagnosis in ET and PV

CME

Diagnostic Precision in Essential Thrombocythemia and Polycythemia Vera

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: February 02, 2026

Expiration: August 01, 2026

Activity

Progress
1 2
Course Completed

References

  1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703-1719.
  2. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-1228.
  3. Thiele J, Kvasnicka HM, Orazi A, et al. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023;98:166-179.
  4. Harrison CN, Vannucchi AM. Closing the gap: genetic landscape of MPN. Blood. 2016;127:276-278.
  5. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15.
  6. Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921-4928.
  7. Durak ZA, Demirci Z, Eşkazan AE. Masked polycythemia vera: diagnostic challenges and clinical implications. Expert Rev Hematol. 2026;19:1-3.
  8. Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1465-1487.
  9. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.
  10. Thiele J, Kvasnicka HM, Gianelli U, et al. Evolution of WHO diagnostic criteria in "classical myeloproliferative neoplasms" compared with the International Consensus Classification. Blood Cancer J. 2025;15:31.
  11. Gianelli U, Thiele J, Orazi A, et al. International consensus classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Arch. 2023;482:53-68.
  12. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179-3184.
  13. Passamonti F, Maffioli M. Update from the latest WHO classification of MPNs: a user's manual. Hematology Am Soc Hematol Educ Program. 2016;2016:534-542.
  14. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379-2390.
  15. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391-2405.
  16. Boldrini V, Loscocco GG, Guglielmelli P, et al. Understanding triple negative myeloproliferative neoplasms and identifying molecular drivers. Curr Hematol Malig Rep. 2026;21:1.
  17. Zoi K, Cross NC. Genomics of myeloproliferative neoplasms. J Clin Oncol. 2017;35:947-954.
  18. He R, Ollila PL, Zhang X, et al. Prevalence of concurrent (double-positive) JAK2, CALR, or MPL mutations and corresponding clinicopathologic features: analysis of 21556 Mayo Clinic NGS studies including 2651 informative cases. Am J Hematol. 2025;100:2431-2435.
  19. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: myeloproliferative neoplasms. v2.2025. Accessed January 28, 2026.
  20. Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36:310-318.
  21. Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769-1770.
  22. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392-397.
  23. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220-2228.